Change of Director's Interest Notice - Dr Russell Basser
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
Starpharma Holdings Limited
ABN
20 078 532 180
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Dr Russell Basser
Date of last notice
16 April 2024
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
-
Date of change
13 September 2024
No. of securities held prior to change
71,428 Ordinary Shares (Direct)
Class
Ordinary Shares
Number acquired
200,000 Ordinary Shares
Number disposed
Nil
Value/Consideration
$18,600 ($0.093 per share)
No. of securities held after change
271,428 Ordinary Shares (Direct)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Note: If consideration is non-cash, provide details and estimated
valuation
+ See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Nature of change
On market purchase
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buyback
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the N/A
trade to proceed during this period?
If prior written clearance was provided, on what date was N/A
this provided?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Share your feedback
Discover